Comparison of statins in hypertriglyceridemia

The American Journal of Cardiology
E A SteinP Laskarzewski

Abstract

In 1996, the first 2 studies using 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor ("statin") therapy in hypertriglyceridemic subjects were published. In subjects with isolated triglyceride elevations who were treated with atorvastatin 5, 20, and 80 mg/day, large and dose-related reductions were noted. In subjects with combined hyperlipidemia treated with 10 mg simvastatin, triglyceride reduction similar to that reported for the 5 mg atorvastatin dose was seen. In response to these findings, we conducted comparative assessments to determine whether all statins are effective in lowering triglyceride levels and whether their effect on triglycerides is related to factors such as drug, dose, and baseline triglyceride levels. To standardize these assessments, we devised a ratio that related changes in triglyceride levels to the known predictable response of low-density lipoprotein (LDL) cholesterol to statins. This triglyceride/LDL cholesterol ratio was obtained by dividing the percent change from baseline in the triglyceride level by the percent change from baseline in the LDL cholesterol level. The triglyceride/LDL cholesterol ratio was initially applied to several published studies, and found to be approximate...Continue Reading

Citations

Oct 8, 1999·Clinica Chimica Acta; International Journal of Clinical Chemistry·P Cullen, G Assmann
Aug 28, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael P DubéUNKNOWN HIV Medical Association of the Infectious Disease Society of America
Mar 8, 2013·Future Cardiology·Yu KataokaStephen J Nicholls
Feb 26, 2014·Nutrients·Tiziana MontalciniArturo Pujia
May 21, 2014·Best Practice & Research. Clinical Endocrinology & Metabolism·Dick C ChanGerald F Watts
Sep 26, 2013·Nature Reviews. Cardiology·Gerald F WattsDick C Chan
Oct 23, 2002·Journal of General Internal Medicine·Michael L Green
Jan 24, 2008·European Journal of Human Genetics : EJHG·Jennifer A SmithSharon L R Kardia
Oct 5, 2011·Current Cardiology Reports·Beatriz G Talayero, Frank M Sacks
Oct 6, 2005·Clinical Chemistry and Laboratory Medicine : CCLM·Despoina M Choumerianou, George V Z Dedoussis
Apr 6, 2004·Diabetes Research and Clinical Practice·Paul N DurringtonKaren Smith
Jan 24, 2003·Clinical Cardiology·Jonathan IsaacsohnYale B Mitchel
Jan 5, 2002·Current Atherosclerosis Reports·Evan A Stein, Donald M Black
Dec 21, 2000·Current Atherosclerosis Reports·P Duriez, J C Fruchart
Aug 24, 2007·Lipids·Vasilios G AthyrosUNKNOWN GREACE Study Collaborative Group
May 1, 2004·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Hiroyuki YamazakiMasaki Kitahara
Jun 18, 2002·Journal of Cellular and Molecular Medicine·C Stancu, A Sima
Aug 9, 2012·The Libyan Journal of Medicine·Dhastagir Sultan SheriffManopriya T Priya
Jun 14, 2003·Pharmacology & Therapeutics·Anthony S WierzbickiAlbert Ferro
Jul 18, 2001·Journal of Diabetes and Its Complications·J A PapadakisD P Mikhailidis
May 19, 2001·Journal of Diabetes and Its Complications·L F FriedT J Orchard
Feb 28, 2001·Diabetes, Obesity & Metabolism·D J Betteridge
Mar 7, 2001·Diabetes, Obesity & Metabolism·P CullenG Assmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.